ATRS · Antares Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.56M | - | $48.19M | $44.98M | $42.08M | - | $40.00M | $32.38M | $33.08M | - |
| Cost of Revenue | - | - | - | - | - | - | $16.52M | $12.48M | $15.05M | - |
| Gross Profit | - | - | - | - | - | - | $23.49M | $19.91M | $18.03M | - |
| R&D | $5.01M | - | $3.92M | $4.05M | $2.64M | - | $2.40M | $2.42M | $2.98M | - |
| SG&A | $20.60M | - | $19.87M | $17.70M | $17.61M | - | $15.23M | $14.45M | $16.42M | - |
| Total Operating Expenses | $44.38M | - | $40.23M | - | - | - | - | - | - | - |
| D&A | $931.0K | - | $738.0K | - | $894.0K | - | - | - | $570.0K | - |
| Operating Income | ($2.82M) | - | $7.96M | $6.79M | $5.39M | - | $5.85M | $3.04M | ($1.37M) | - |
| Interest Expense | $174.0K | - | $750.0K | $1.14M | $962.0K | - | $782.0K | $967.0K | $1.06M | - |
| Income Tax | ($817.0K) | - | $1.83M | $1.14M | $590.0K | - | - | - | - | - |
| Net Income | ($2.32M) | - | $5.39M | $4.42M | $3.79M | - | $5.00M | $2.17M | ($2.36M) | - |
| EPS - Basic | ($0.01) | - | $0.03 | $0.01 | ($0.01) | - | $0.03 | - | - | - |
| EPS - Diluted | ($0.01) | - | $0.03 | $0.01 | ($0.01) | - | $0.01 | - | - | - |
Balance Sheet
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61.72M | $65.91M | $57.37M | $45.13M | $55.65M | $53.14M | $50.17M | $43.56M | $33.81M | $23.20M |
| Accounts Receivable | $58.13M | $56.70M | $54.47M | $54.22M | $42.94M | $42.22M | $42.51M | $34.29M | $31.41M | $35.07M |
| Inventory | $11.59M | $11.54M | $16.49M | $18.64M | $19.61M | $18.22M | $19.81M | $19.61M | $17.31M | $16.00M |
| Accounts Payable | $19.88M | $17.06M | $12.88M | $15.80M | $16.76M | $16.19M | $18.02M | $18.07M | $18.18M | $12.90M |
| Current Assets | $171.59M | $174.27M | $133.43M | $127.96M | $133.52M | $126.59M | $125.12M | $115.76M | $112.33M | $108.45M |
| Total Assets | $255.66M | $257.50M | $216.74M | $212.62M | $218.46M | $212.53M | $155.57M | $143.12M | $136.80M | $132.75M |
| Current Liabilities | $55.73M | $58.93M | $52.53M | $71.97M | $72.14M | $63.20M | $50.55M | $39.97M | $37.26M | $32.41M |
| Long-term Debt | $17.89M | $18.24M | $18.40M | $3.34M | $14.77M | $24.67M | $34.36M | $40.65M | $40.52M | $40.40M |
| Total Liabilities | $79.89M | $81.75M | $75.91M | $80.59M | $92.23M | $93.42M | $90.33M | $85.80M | $83.01M | $78.25M |
| Stockholders' Equity | $175.77M | $175.76M | $140.83M | $132.03M | $126.22M | $119.11M | $65.24M | $57.33M | $53.80M | $54.50M |
| Retained Earnings | ($178.66M) | ($176.34M) | ($209.02M) | ($214.41M) | ($218.83M) | ($222.63M) | ($274.01M) | ($279.01M) | ($281.18M) | ($278.83M) |
Cash Flow
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.88M) | - | - | - | $1.98M | - | - | - | $5.58M | - |
| Investing Cash Flow | $666.0K | - | - | - | ($1.18M) | - | - | - | $5.36M | - |
| Financing Cash Flow | $17.0K | - | - | - | $1.72M | - | - | - | ($326.0K) | - |
| CapEx | $81.0K | - | - | - | $1.18M | - | - | - | $641.0K | - |
| Free Cash Flow | ($4.96M) | - | - | - | $794.0K | - | - | - | $4.94M | - |
Ratios
| Metric | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 58.7% | 61.5% | 54.5% | - |
| Operating margin | -6.8% | - | 16.5% | 15.1% | 12.8% | - | 14.6% | 9.4% | -4.1% | - |
| EBITDA margin | -4.5% | - | 18.1% | - | 14.9% | - | - | - | -2.4% | - |
| Net margin | -5.6% | - | 11.2% | 9.8% | 9.0% | - | 12.5% | 6.7% | -7.1% | - |
| Free cash flow margin | -11.9% | - | - | - | 1.9% | - | - | - | 14.9% | - |
| FCF / Net income | 2.14 | - | - | - | 0.21 | - | - | - | -2.10 | - |
| R&D / Revenue | 12.1% | - | 8.1% | 9.0% | 6.3% | - | 6.0% | 7.5% | 9.0% | - |
| SG&A / Revenue | 49.6% | - | 41.2% | 39.4% | 41.8% | - | 38.1% | 44.6% | 49.6% | - |
| Effective tax rate | - | - | 25.3% | 20.5% | 13.5% | - | - | - | - | - |
| Return on assets | -0.9% | - | 2.5% | 2.1% | 1.7% | - | 3.2% | 1.5% | -1.7% | - |
| Return on equity | -1.3% | - | 3.8% | 3.3% | 3.0% | - | 7.7% | 3.8% | -4.4% | - |
| Return on invested capital | -1.2% | - | 3.7% | 4.0% | 3.3% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.08 | 2.96 | 2.54 | 1.78 | 1.85 | 2.00 | 2.47 | 2.90 | 3.01 | 3.35 |
| Quick ratio | 2.87 | 2.76 | 2.23 | 1.52 | 1.58 | 1.71 | 2.08 | 2.41 | 2.55 | 2.85 |
| Cash ratio | 1.11 | 1.12 | 1.09 | 0.63 | 0.77 | 0.84 | 0.99 | 1.09 | 0.91 | 0.72 |
| Leverage | ||||||||||
| Debt / Equity | 0.10 | 0.10 | 0.13 | 0.03 | 0.12 | 0.21 | 0.53 | 0.71 | 0.75 | 0.74 |
| Debt / Assets | 0.07 | 0.07 | 0.08 | 0.02 | 0.07 | 0.12 | 0.22 | 0.28 | 0.30 | 0.30 |
| Debt / EBITDA | - | - | 2.11 | - | 2.35 | - | - | - | - | - |
| Interest coverage | -16.2x | - | 10.6x | 6.0x | 5.6x | - | 7.5x | 3.1x | -1.3x | - |
| Equity multiplier | 1.45 | 1.47 | 1.54 | 1.61 | 1.73 | 1.78 | 2.38 | 2.50 | 2.54 | 2.44 |
| Liabilities / Assets | 0.31 | 0.32 | 0.35 | 0.38 | 0.42 | 0.44 | 0.58 | 0.60 | 0.61 | 0.59 |
| Efficiency | ||||||||||
| Asset turnover | 0.16 | - | 0.22 | 0.21 | 0.19 | - | 0.26 | 0.23 | 0.24 | - |
| Inventory turnover | - | - | - | - | - | - | 0.83 | 0.64 | 0.87 | - |
| Days sales outstanding | 511d | - | 413d | 440d | 372d | - | 388d | 387d | 347d | - |
| Days inventory outstanding | - | - | - | - | - | - | 438d | 574d | 420d | - |
| Days payable outstanding | - | - | - | - | - | - | 398d | 529d | 441d | - |
| Cash conversion cycle | - | - | - | - | - | - | 427d | 431d | 325d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -1.2% | - | 20.5% | 38.9% | 27.2% | - | 16.6% | 13.9% | 42.1% | - |
| Revenue CAGR (3y) | 21.3% | - | 47.4% | 47.0% | 49.1% | - | 38.5% | 34.1% | 40.2% | - |
| Revenue CAGR (5y) | 28.2% | - | 29.0% | 29.8% | 27.9% | - | 29.3% | 17.6% | 31.7% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | 10.6% | 24.5% | 46.1% | - |
| Operating income growth (YoY) | - | - | 36.2% | 123.1% | - | - | 193.1% | - | 72.5% | - |
| Net income growth (YoY) | - | - | 7.9% | 103.2% | - | - | 379.0% | - | 57.5% | - |
| EPS growth (YoY) | 0.0% | - | 200.0% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -83.9% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 39.2% | 47.6% | 115.9% | 130.3% | 134.6% | 118.6% | 46.9% | 38.0% | 26.1% | 39.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$310.65M totalProduct$126.67M · 40.8%
Proprietary Product$80.02M · 25.8%
Partnered Product$46.65M · 15.0%
Royalty$37.69M · 12.1%
Licensing And Development Revenue$19.62M · 6.3%
Geographic
$183.98M totalUS$178.29M · 96.9%
Europe$5.69M · 3.1%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing ANTARES PHARMA against the 5 most active filers in the same SIC group.